Abscint

Recent Finacing

Equity

Recent Raise

$1.2M

ABSCINT is a VUB spin-off developing single-domain antibody radiopharmaceutical diagnostics for rapid whole-body PET visualization of molecular markers, with clinical-stage programs for HER2 cancer mapping and cardiac sarcoidosis detection.

Founded 2022

Brussels Hoofdstedelijk Gewest, Belgium

1-10

Private

abscint.com

Highlights

Focus Areas

Biotechnology

Health Care

Health Diagnostics

Medical

Recent Investors

K

Financials

$4.9M

Total Raised

2

Funding rounds

6

Investors

Team

Upgrade to view the team

See the team members at Abscint.